-
Mashup Score: 18Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus | NEJM - 25 day(s) ago
Patients with severe aortic stenosis and a small aortic annulus are at risk for impaired valvular hemodynamic performance and associated adverse cardiovascular clinical outcomes after transcatheter…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 15
– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – …
Source: www.globenewswire.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 41A Placebo-Controlled Trial of PCI for Stable Angina | NEJM - 1 month(s) ago
Correspondence from The New England Journal of Medicine — A Placebo-Controlled Trial of PCI for Stable Angina
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2Amylyx's ALS treatment Relyvrio fails PhIII study, biotech to consider withdrawing drug - 2 month(s) ago
Relyvrio, Amylyx’s FDA-approved ALS drug, has failed a crucial Phase III trial, the company said on Friday, a major blow to what had been considered one of the few significant options available for the treatment of the deadly neurodegenerative disease. The failure is almost certain to put access to the
Source: endpts.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5Remembering Dr. Merrill Benson - Amyloidosis Research Consortium - 2 month(s) ago
The Amyloidosis Research Consortium extends our deepest, heartfelt condolences to the family and friends of Dr. Merrill Benson, world renowned amyloidosis expert, who passed away on September 11, 2021.
Source: arci.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 6
Don’t miss what’s happeningPeople on X are the first to know.Log inSign upSettingsPostPinak Shah, MD@PinakShahMDwhy I would not want another trial. Yes, could have done better (sham control). But we now have a therapy for a difficult problem that makes people feel better and is incredibly safe. Appropriate pt selection key and we have to beware of indication creep.11:45 AM · Feb 20, 2024665…
Source: x.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5Longevity of the Placebo Effect in the Therapeutic Angiogenesis and Laser Myocardial Revascularization Trials in Patients With Coronary Heart Disease - 2 month(s) ago
The long-term beneficial effects of placebo therapy were evaluated in angiogenesis and laser myocardial revascularization trials in patients who had end-stage coronary heart disease. Improvements in mean angina class, exercise treadmill time, and quality of life were mostly maintained at 30 ± 6 months of follow-up. Persistence of effect cannot be used as evidence of efficacy, and double-blinded trials are essential in this patient population.
Source: www.ajconline.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 19
The executive summary questions the open-label trial, noting that benefit was driven by a softer QoL endpoint.
Source: www.tctmd.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials - 3 month(s) ago
Congestion is a key driver of morbidity and mortality in heart failure. Implanted haemodynamic monitoring devices might allow early identification and management of congestion. Here, we provide a state-of-the-art review of implanted haemodynamic monitoring …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
@gcfmd Mortality data are shaky! What happens when mortality data are added from MONITOR-HF (HR 0.96, 0.63-1.46)? LAPTOP device is not commercialized & trial was stopped due to safety concerns. And how are we to reconcile mortality results with this study? https://t.co/RnXqNfhKEF https://t.co/9IUbv2KkIk
-
-
Mashup Score: 3Breakthrough Devices Program - 3 month(s) ago
This guidance proposes select updates to the guidance that clarify how the program may be applicable to certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions in populations impacted by health
Source: www.fda.govCategories: General Medicine News, CardiologistsTweet
1/ Noninferiority lies in the eyes of the beholder! PEP: death, disabling stroke or HHF Expected BEV rate: 16% Noninferiority margin: 8% RD (? wide) or RR 1.5 Observed BEV rate: 10.6% Key result: 9.4% vs 10.6%, RD −1.2%, -4.9 to 2.5 HR 0.90, 0.56-1.43 https://t.co/ykol0D94du